Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations

1. Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations

3. Program Goals

11. Serum Tumor Markers for Monitoring Disease Progression in Patients With Advanced Breast Cancer

12. Case 1: 48-Year-Old Woman Diagnosed With Recurrent ER/PR-Positive, HER2-Positive Breast Cancer (cont)

13. Case 1: 48-Year-Old Woman Diagnosed With Recurrent ER/PR-Positive, HER2-Positive Breast Cancer (cont)

17. Tamoxifen vs Aromatase Inhibition in Hormone Receptor-Positive MBC

18. Case 2: 65-Year-Old Women Diagnosed With Recurrent ER/PR-Negative, HER2-Positive Breast Cancer

19. Case 2: 65-year-old Women Diagnosed With Recurrent ER/PR-Negative, HER2-Positive Breast Cancer (cont)

27. Phase 3 CLEOPATRA Trial: Safety

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)

37. References

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)